01615nas a2200229   4500000000100000008004100001260001600042653002400058653002200082653002500104653001700129100001300146700001800159700002600177700001800203700001200221700003100233245005900264300001100323520103700334022001401371       2020                            d  bElsevier BV10aInorganic Chemistry10aOrganic Chemistry10aAnalytical Chemistry10aSpectroscopy1 aSousa ML1 aSarraguça MC1 aOliveira dos Santos A1 aSarraguça JM1 aLopes J1 aRoberto da Silva Ribeiro P00aA new salt of clofazimine to improve leprosy treatment  a1282263 aIn this work, a new salt of clofazimine (CFZ) with 4-aminobenzoic acid (PABA is described. CFZ is an antibiotic drug used in the treatment of leprosy. This drug has low absorption when administered orally because of its low water solubility, contributing to the reduction of bioavailability, limiting its application. Towards the augmentation of the bioavailability of CFZ, we propose in this work the development of a salt. The new product CFZ+–PABA– (1:1) was synthesized through liquid assisted grinding method and characterized by powder X-ray diffraction, mid-infrared spectroscopy, and differential scanning calorimetry. The investigations provided evidence of the formation of a new salt. The interaction involves proton transfer between PABA and CFZ forming  motif in carboxylate region (COO−) of PABA and imines regions (N–H/N+–H) of CFZ. According to the analyses, the stoichiometric ratio of salt formation is 1:1. The salt dissolution profile shows the product is 5.0 folds more soluble than the CFZ free base.  a0022-2860